Koers Emmaus Life Sciences, Inc. Other OTC
Aandelen
EMMA
US29137T1016
Biotechnologie & Medisch Onderzoek
Omzet 2021 | 20,61 mln. 19,14 mln. | Omzet 2022 | 18,39 mln. 17,08 mln. | Marktkapitalisatie | 12,9 mln. 11,98 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2021 | -15 mln. -13,93 mln. | Nettowinst (verlies) 2022 | -10 mln. -9,29 mln. | EV/omzet 2021 | 4,97 x |
Nettoschuld 2021 | 20,13 mln. 18,69 mln. | Nettoschuld 2022 | 28,8 mln. 26,74 mln. | EV/omzet 2022 | 2,27 x |
K/w-verhouding 2021 |
-5,16
x | K/w-verhouding 2022 |
-1,21
x | Werknemers | - |
Dividendrendement 2021 * |
-
| Dividendrendement 2022 |
-
| Vrij verhandelbaar | 48,23% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
George Sekulich
PSD | President | 59 | 01-05-19 |
Willis Lee
CHM | Chairman | 64 | 17-07-19 |
Yasushi Nagasaki
DFI | Director of Finance/CFO | 57 | 01-05-11 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Wei Peu Zen
BRD | Director/Board Member | 71 | 17-07-19 |
Willis Lee
CHM | Chairman | 64 | 17-07-19 |
Ian Zwicker
BRD | Director/Board Member | 77 | 17-07-19 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+17,96% | 44,96 mld. | |
+48,77% | 41,85 mld. | |
+1,17% | 42,65 mld. | |
-4,27% | 29,04 mld. | |
+11,42% | 26,08 mld. | |
-21,39% | 19,03 mld. | |
+4,86% | 12,75 mld. | |
+27,29% | 12,06 mld. | |
-3,50% | 11,75 mld. |